Libby Morris

Libby Morris serves as Vice President and Program Team Lead at Nurix Therapeutics since February 2025, overseeing the development of the CNS-penetrant BTK degrader NX 5948 for heme malignancies. Previously, Libby held the role of Program Team Lead at Amgen, focusing on a Bispecific T-cell Engager and leading pivotal study design efforts. At Gilead Sciences, Libby acted as Program Strategy Leader for an oncology and hematology asset covering 14 indications. Experience at Genentech included serving as Commercial Development Director and Director of Oncology Early Medicines Development, where Libby was involved in lifecycle management and commercial direction for cancer therapies. Libby's earlier roles spanned positions at Roche Molecular Systems in global medical marketing and at Bristol Myers Squibb in various marketing leadership capacities, including the launch of Erbitux and Ixempra. Additional experience includes leadership roles in marketing at Roche and Boehringer Ingelheim, specifically in the HIV/AIDS therapeutic area.